

immune effector cells, comprising administering a conjugate to an animal whereby activation, proliferation, migration of the immune effector cells is inhibited wherein:

the conjugate comprises a targeted agent or a portion thereof and a chemokine receptor targeting agent or a portion thereof sufficient to bind to the chemokine receptor and facilitate internalization of the conjugate;

the chemokine receptor targeting agent is a chemokine, an antibody that specifically binds to a chemokine receptor or a fragment of the chemokine or antibody, wherein the chemokine, antibody or fragment thereof binds to the receptor and internalizes the targeted agent in a cell;

the targeted agent or portion thereof, when internalized in a cell, alters metabolism or gene expression in the cell, regulates or alters protein synthesis in the cell, inhibits proliferation of the cell or kills the cell; and

the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.

31. (Twice Amended) The method of claims 29, wherein the treated pathology underlies a disorder or disease state that is selected from the group consisting of CNS injury, CNS inflammatory diseases, neurodegenerative disorders, heart disease, inflammatory eye diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory kidney or renal diseases, inflammatory lung diseases, inflammatory nasal diseases, inflammatory thyroid diseases, inflammatory responses associated with bacterial or viral infections and cytokine-regulated cancers.

65. (Amended) The method of claim 29, wherein the chemokine receptor targeting agent is a chemokine or a sufficient portion thereof to specifically bind to a chemokine receptor and to facilitate internalization of the conjugate.

72. (Amended) A method for inhibiting activation, proliferation or migration of immune cells, comprising contacting immune cells with a conjugate

that comprises a targeted agent or a portion thereof and a chemokine receptor targeting agent whereby activation, proliferation, migration of the immune cells is inhibited, wherein:

the targeted agent or portion thereof is a toxin;

the chemokine receptor targeting agent is a chemokine or a fragment of thereof that binds to a chemokine receptor and internalizes the targeted agent; and

the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.

86. (Amended) A method of treating a disease or disorder associated with an inflammatory response, comprising:

identifying immune cells that are activated in the disease or disorder;

identifying chemokine receptors expressed on the cells;

preparing a conjugate or plurality thereof containing toxin linked to a chemokine or a plurality of chemokines that specifically bind to the identified chemokine receptors and effect or facilitate internalization of the toxin into the cells; and

contacting the immune cells with the conjugate or plurality thereof.

REMARKS

A check for the requisite fees for a three month extension of time and Notice of Appeal accompanies this response. Any fees that may be due in connection with this paper or with this application may be charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.

Claims 26-29, 31, 32, 34-38, 40, 42, 44-46, 48-54, 57 and 65-87, are presently pending in this application. Claims 29, 31, 65, 72 and 86 are amended. Claims 29 and 31 are amended to more particularly point out that the methods are designed to treat the common underlying pathology that underlies a